The vaccines currently used in the U.S. still offer strong protection against severe COVID-19 disease and death — especially if people have gotten a booster dose. But those vaccines target the original coronavirus strain and their effectiveness against any infection dropped markedly when the super-contagious omicron mutant emerged.
Pfizer and its partner BioNTech studied two different ways of updating their shots — targeting just omicron, or a combination booster that adds omicron protection to the original vaccine. They also tested whether to keep today’s standard dosage — 30 micrograms — or to double the shots’ strength. “Based on these data, we believe we have two very strong omicron-adapted candidates,” Pfizer CEO Albert Bourla said in a statement.But many experts say combination shots may be the best approach because they would retain the proven benefits of the original COVID-19 vaccine while adding new protection against omicron. And Pfizer said a month after people received its combo shot, they had a 9 to 11-fold increase in omicron-fighting antibodies. That’s more than 1.
Moderna recently announced similar results from tests of its combination shot, what scientists call a “bivalent” vaccine.
Tweaking it, with no long term testing. It’s a “shot” in the dark. People have to be out of their minds to trust them.
Maybe they could make one that works. Maybe they could make one like they advertised it would be.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: SpectrumNews1TX - 🏆 333. / 59 Read more »
Source: WBUR - 🏆 274. / 63 Read more »
Source: NBCLA - 🏆 319. / 59 Read more »
Source: wjxt4 - 🏆 246. / 63 Read more »
Source: wsfa12news - 🏆 338. / 59 Read more »